Information Provided By: 
Fly News Breaks for April 14, 2016
UTHR, RTRX, RPTP, MDCO, ITCI, DERM, DEPO, AMAG, AKRX, ACAD
Apr 14, 2016 | 08:12 EDT
Leerink analyst Joseph Schwartz believes partnership and acquisition activity will reemerge as a key feature in the biopharma industry in the coming months based on pharma and large cap biotech's continued assertions that they are searching for new assets. The analyst's top ten list of future targets include ACADIA (ACAD), Akorn (AKRX), AMAG Pharmaceuticals (AMAG), Depomed (DEPO), Dermira (DERM), Intra-Cellular (ITCI), The Medicines Co. (MDCO), Retrophin (RTRX), Raptor Pharmaceutical (RPTP) and United Therapeutics (UTHR).
News For ACAD;AKRX;AMAG;DEPO;DERM;ITCI;MDCO;RPTP;RTRX;UTHR From the Last 2 Days
ITCI
Apr 19, 2024 | 11:12 EDT
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Intra-Cellular Therapies... To see the rest of the story go to thefly.com. See Story Here
ITCI
Apr 18, 2024 | 11:18 EDT
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Intra-Cellular Therapies... To see the rest of the story go to thefly.com. See Story Here
ITCI
Apr 17, 2024 | 22:49 EDT
ACAD
Apr 17, 2024 | 16:07 EDT
ITCI
Apr 17, 2024 | 07:01 EDT
ITCI
Apr 17, 2024 | 06:54 EDT
Baird analyst Joel Beatty raised the firm's price target on Intra-Cellular to $103 from $83 and keeps an Outperform rating on the shares. The firm increased its price target after successful topline ph3 results for Caplyta in major depressive disorder (MDD) as they view the efficacy as at or above investor expectations, and safety as generally in line with expectations.
